Sera Prognostics halts PRIME study enrollment due to reaching efficacy endpoint

Sera Prognostics announced that the Data Safety Monitoring Board overseeing its pivotal Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs study recommended stopping enrollment due to efficacy, reporting that either of the co-primary endpoints met the stopping criteria for statistical significance at the pre-planned interim analysis. The company has adopted the DSMB’s recommendation and will stop PRIME study enrollment to focus on analyzing and reporting the available data.